{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:45:13Z","timestamp":1784918713266,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015489","name":"Polka Dot Mama Melanoma Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015489","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jss.2018.11.045","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T01:10:38Z","timestamp":1545268238000},"page":"209-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy"],"prefix":"10.1016","volume":"236","author":[{"given":"Charles J.","family":"Puza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Schell","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Terando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Harrison","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Hanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K.S.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2018.11.045_bib1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2018.11.045_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2018.11.045_bib3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2018.11.045_bib4","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jss.2018.11.045_bib5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2018.11.045_bib6","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jss.2018.11.045_bib7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2018.11.045_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in Untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2018.11.045_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","article-title":"Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study","volume":"36","author":"Callahan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2018.11.045_bib10","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2018.11.045_bib11","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2018.11.045_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-017-0013-8","article-title":"Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma","volume":"2","author":"Reuben","year":"2017","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.jss.2018.11.045_bib13","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-17-0114","article-title":"Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions","volume":"23","author":"Nishino","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2018.11.045_bib14","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1245\/s10434-013-2999-1","article-title":"Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma","volume":"20","author":"Gyorki","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2018.11.045_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2018.11.045_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/CMR.0000000000000355","article-title":"Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events","volume":"27","author":"Diamantopoulos","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jss.2018.11.045_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0b013e31824bc981","article-title":"Surgery for distant melanoma metastasis","volume":"18","author":"Leung","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.jss.2018.11.045_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000106575","article-title":"S-100B and FDG-PET\/CT in therapy response assessment of melanoma patients","volume":"215","author":"Strobel","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jss.2018.11.045_bib19","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/0008-5472.CAN-16-3346","article-title":"Granzyme B PET imaging as a predictive biomarker of immunotherapy response","volume":"77","author":"Larimer","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2018.11.045_bib20","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2018.11.045_bib21","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jss.2018.11.045_bib22","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma","volume":"23","author":"Vilain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2018.11.045_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.2008.17.1777","article-title":"Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694","volume":"27","author":"Tarhini","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2018.11.045_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11912-017-0575-8","article-title":"The role of surgery for melanoma in an era of effective systemic therapy","volume":"19","author":"Raigani","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jss.2018.11.045_bib25","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1200\/JCO.2017.35.15_suppl.9586","article-title":"Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: updated data from the OpACIN trial and first immunological analyses","volume":"35","author":"Rozeman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2018.11.045_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2018.11.045_bib27","series-title":"Outcomes of Patients with Metastatic Melanoma Selected for Surgery After Immunotherapy","author":"Bello","year":"2018"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480418308400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480418308400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T12:18:26Z","timestamp":1589977106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480418308400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":27,"alternative-id":["S0022480418308400"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2018.11.045","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2018.11.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}